Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China (Q39548089)

13 September 2017

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China (English)

1 reference

13 September 2017

0 references

1 reference

1 reference

Lan Gao

1

1 reference

PubMed ID

23006540

13 September 2017

Fei-Li Zhao

series ordinal

2

1 reference

PubMed ID

23006540

13 September 2017

Shu-Chuen Li

series ordinal

3

1 reference

13 September 2017

24 September 2012

1 reference

International Journal of Technology Assessment in Health Care

13 September 2017

1 reference

13 September 2017

28

1 reference

13 September 2017

436-444

1 reference

13 September 2017

4

1 reference

Prevalence of diabetes mellitus in China

13 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Peripheral vascular disease in Type 2 diabetic Chinese patients: associations with metabolic indices, concomitant vascular disease and genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Revealing the cost of Type II diabetes in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Performance of HbA(1c) for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

7 January 2021

Assessing the impact of complications on the costs of Type II diabetes.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

7 January 2021

Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

7 January 2021

Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000608

7 January 2021

10.1017/S0266462312000608

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

23006540